Dendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company's product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company's product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:DNDN
- CUSIP: 24823Q10
- Web: N/A
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.32
- P/E Growth: N/A
Frequently Asked Questions for Dendreon (NASDAQ:DNDN)
What is Dendreon's stock symbol?
Dendreon trades on the NASDAQ under the ticker symbol "DNDN."
How were Dendreon's earnings last quarter?
Dendreon Co. (NASDAQ:DNDN) announced its quarterly earnings results on Monday, November, 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The firm earned $73.10 million during the quarter, compared to analysts' expectations of $78.72 million. Dendreon's quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.44) earnings per share. View Dendreon's Earnings History.
Who are some of Dendreon's key competitors?
Some companies that are related to Dendreon include Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH) and Kite Pharma (KITE).
How do I buy Dendreon stock?
Shares of Dendreon can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Dendreon stock cost?
One share of Dendreon stock can currently be purchased for approximately $0.13.
Consensus Ratings for Dendreon (NASDAQ:DNDN) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Dendreon (NASDAQ:DNDN)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Dendreon (NASDAQ:DNDN)Earnings History by Quarter for Dendreon (NASDAQ:DNDN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/10/2014||Q3||($0.10)||($0.14)||$78.72 million||$73.10 million||View||N/A|
|8/11/2014||($0.25)||($0.10)||$73.37 million||$82.16 million||View||N/A|
|5/8/2014||Q114||($0.28)||($0.24)||$69.19 million||$68.70 million||View||Listen|
|3/3/2014||Q413||($0.37)||($0.17)||$73.59 million||$74.80 million||View||Listen|
|11/12/2013||Q313||($0.42)||($0.44)||$76.60 million||$68.00 million||View||Listen|
|8/8/2013||Q2 2013||($0.42)||($0.45)||$75.61 million||$73.30 million||View||N/A|
|5/9/2013||Q1 2013||($0.47)||($0.48)||$80.15 million||$67.60 million||View||N/A|
|2/25/2013||Q4 2012||($0.56)||($0.26)||$82.88 million||$85.49 million||View||N/A|
|11/2/2012||Q312||($0.75)||($0.33)||$80.68 million||$78.00 million||View||N/A|
Earnings Estimates for Dendreon (NASDAQ:DNDN)
Current Year EPS Consensus Estimate: $-0.730 EPS
Next Year EPS Consensus Estimate: $-0.400 EPS
Dividend History for Dendreon (NASDAQ:DNDN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Dendreon (NASDAQ:DNDN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Dendreon (NASDAQ:DNDN)
Latest Headlines for Dendreon (NASDAQ:DNDN)
Dendreon (DNDN) Chart for Saturday, May, 27, 2017